Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Designing HDAC-PROTACs: Lessons Learned So Far
Fabian Fischer, Leandro A. Alves Avelar, Laoise Murray, et al.
Future Medicinal Chemistry (2021) Vol. 14, Iss. 3, pp. 143-166
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 141
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 72
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 46
HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 29
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Dušan Ružić, Nemanja Djoković, Tatjana Srdić‐Rajić, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 209-209
Open Access | Times Cited: 37
Current trends in development of HDAC-based chemotherapeutics
Narges Cheshmazar, Maryam Hamzeh‐Mivehroud, Hojjatollah Nozad Charoudeh, et al.
Life Sciences (2022) Vol. 308, pp. 120946-120946
Closed Access | Times Cited: 33
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
Cristina Maccallini, Alessandra Ammazzalorso, Barbara De Filippis, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 667-667
Open Access | Times Cited: 27
Development of the first non-hydroxamate selective HDAC6 degraders
Tim Keuler, Beate König, Nico Bückreiß, et al.
Chemical Communications (2022) Vol. 58, Iss. 79, pp. 11087-11090
Closed Access | Times Cited: 27
Discovery of highly potent HDAC8 PROTACs with anti-tumor activity
Chunlong Zhao, Deng Chen, Feng‐Zhi Suo, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106546-106546
Open Access | Times Cited: 16
A Comprehensive Primer and Review of PROTACs and Their In Silico Design
Jacopo Zattoni, Paola Vottero, Gea Carena, et al.
Computer Methods and Programs in Biomedicine (2025) Vol. 264, pp. 108687-108687
Open Access
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington’s Disease Pathology
Natsuko Macabuag, William Esmieu, Perla Breccia, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 18, pp. 12445-12459
Open Access | Times Cited: 23
PROTAC: targeted drug strategy. Principles and limitations
O. A. Koroleva, Yu. V. Dutikova, A.V. Trubnikov, et al.
Russian Chemical Bulletin (2022) Vol. 71, Iss. 11, pp. 2310-2334
Open Access | Times Cited: 22
Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours
Yu Chen, Zitong Gao, Isam Mohd‐Ibrahim, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 2
Open Access | Times Cited: 4
Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)
India M. Baker, Joshua P. Smalley, Khadija A Sabat, et al.
Biochemistry (2022) Vol. 62, Iss. 3, pp. 645-656
Open Access | Times Cited: 20
Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease
Yan Li, Shuxian Lin, Zhicheng Gu, et al.
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 76, pp. 129015-129015
Closed Access | Times Cited: 20
Fluorescence theranostic PROTACs for real-time visualization of ERα degradation
Xiaohua Wang, Lilan Xin, Xiaofei Deng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116184-116184
Closed Access | Times Cited: 3
PROTAC chemical probes for histone deacetylase enzymes
Urvashi Patel, Joshua P. Smalley, James T. Hodgkinson
RSC Chemical Biology (2023) Vol. 4, Iss. 9, pp. 623-634
Open Access | Times Cited: 9
PROTAC‐Mediated HDAC7 Protein Degradation Unveils Its Deacetylase‐Independent Proinflammatory Function in Macrophages
Kailibinuer Kadier, Tian Niu, Baoli Ding, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy
Danfeng Cao, Xinyu Zhou, Qian Guo, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?
Yasir S. Raouf, Carlos Moreno–Yruela
JACS Au (2024) Vol. 4, Iss. 11, pp. 4148-4161
Open Access | Times Cited: 1
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues
Marta Pichlak, Tomasz Sobierajski, K. M. Błażewska, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 4
HDACs as an emerging target in endocrine tumors: a comprehensive review
E. Klieser, Bettina Neumayer, Pietro Di Fazio, et al.
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 2, pp. 143-154
Closed Access | Times Cited: 3
Dietary γ-mangostin triggers immunogenic cell death and activates cGAS signaling in acute myeloid leukemia
Zi‐Jie Long, Jundan Wang, Sheng‐Xiang Qiu, et al.
Pharmacological Research (2023) Vol. 197, pp. 106973-106973
Open Access | Times Cited: 3
Design, Synthesis, and Antitumor Activity Evaluation of Polyamine Protac Conjugates as Degraders of Histone Deacetylase
Wentian Chen, Zeng Xianming, Chaonan Tang, et al.
(2024)
Closed Access
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access
Page 1 - Next Page

Scroll to top